south korea comes to the fore in biosimilars space
TRANSCRIPT
South Korea Comes to the Fore in Biosimilars Space
Powered by Small World Social
www.biolink.us
Powered by Small World Social
Aided by government
funding and big pharma
partnerships, South Korea is
staking its claim on
biosimilars, with Celltrion
and Samsung the main
contenders.
2Biolink.us
Powered by Small World Social
South Korea is pushing to be a leader in
the biopharmaceuticals field, so says a
recent Financial Times report. While that
country’s Celltrion is already a big player
in manufacturing, partnering with Pfizer-
owned Hospira, Samsung’s more recent
foray into the research and development
of biosimilars in particular should be
interesting to watch, given the company
continues to take a bite out of Apple’s
market share in the
smartphone/smartwatch space.
3Biolink.us
Powered by Small World Social
Samsung has partnered with U.S. pharma
company Biogen to form Samsung
Bioepis to develop and manufacture
biosimilars. It has also secured a
marketing agreement with another U.S.
group, Merck.
4Biolink.us
Powered by Small World Social
According to the Financial Times article,
South Korea wants “a big share of the
$110 billion of value that Citigroup
expects to flow from [originator biologics]
companies to biosimilars over the next
decade. Seoul has set a goal to increase
pharmaceutical exports to Won23tn
(USD$20.5 billion) by 2020 – up tenfold
from the 2012 figure – when it wants to
have three of the world’s top 50 pharma
companies”.
5Biolink.us
Powered by Small World Social
Celltrion’s Remsima/Inflectra was the
first copy of Johnson & Johnson/Merck’s
rheumatoid arthritis drug Remicade, the
world’s third best-selling drug last year
with sales of $10 billion. Launched in
Europe in February, this biosimilar is now
sold in 40 countries worldwide. And
Merck took a hit earlier in the year when
Orion Oyj, the company marketing
Remsima in Norway, cut the local price
for the drug by 69 per cent, nabbing half
the market in that country.
6Biolink.us
Powered by Small World Social
By partnering with Samsung Bioepis,
Merck could make up for this, given
Samsung Bioepis is awaiting European
regulatory approval for its own Remicade
copy, along with their copy of another
arthritis drug, Pfizer/Amgen’s Enbrel. And
with promising clinical trial data for the
two drugs presented at the European
League Against Rheumatism (EULAR)
Annual Congress in Rome in June,
approvals may not be far off.
7Biolink.us
Powered by Small World Social
By partnering with Samsung Bioepis,
Merck could make up for this, given
Samsung Bioepis is awaiting European
regulatory approval for its own Remicade
copy, along with their copy of another
arthritis drug, Pfizer/Amgen’s Enbrel. And
with promising clinical trial data for the
two drugs presented at the European
League Against Rheumatism (EULAR)
Annual Congress in Rome in June,
approvals may not be far off.
8Biolink.us
Powered by Small World Social
An article in FiercePharmaAsia.com
quoted Samsung Bioepis as saying it
could launch its Enbrel biosimilar in
South Korea late this year and in Europe
in early 2016.
Read More on BioLink:
https://biolink.smallworldsocial.com/porta
l#/?id=
557f01b6aae3895e3b5a910f 9Biolink.us
Powered by Small World Social
www.biolink.us
Visit:https://www.smallworldsocial.com/biolink/ to get the latest in biosimilar news curated from around the world
Want to read more about biosimilars?